Register Login

Kiniksa Pharmaceuticals (KNSA)

(10% Negative) Kiniksa Pharmaceuticals (KNSA) Announces Delay in million Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:31 p.m.

    📋 Kiniksa Pharmaceuticals (KNSA) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 17:22:53

    Event Type: Clinical Trial Update

    Event Details:

    Kiniksa Pharmaceuticals (KNSA) Announces Clinical Trial Update Kiniksa Pharmaceuticals (KNSA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million, treatment
    • Clinical Stage: Phase 1, Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: “IL-1α & IL-1β
    • Updated Timeline: the end of 2025
      • expected in the second half of 2026
      • expected in 2H 2026

    🔬 Clinical Development Pipeline (Kiniksa Pharmaceuticals):

    Product Type Development Stage Therapeutic Area Source
    KPL-387 DRUG Phase PHASE2 Recurrent Pericarditis ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Pericarditis ClinicalTrials.gov
    Vixarelimab DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    Placebo supplements OTHER Approved Monoclonal Gammopathy of Undetermined Significance ClinicalTrials.gov
    Whole Foods Plant-based Diet OTHER Approved Monoclonal Gammopathy of Undetermined Significance ClinicalTrials.gov
    ISA101b BIOLOGICAL Phase PHASE2 HPV-Related Squamous Cell Carcinoma ClinicalTrials.gov
    Cisplatin DRUG Phase PHASE2 HPV-Related Squamous Cell Carcinoma ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE2 HPV-Related Squamous Cell Carcinoma ClinicalTrials.gov
    IMRT (Intensity Modulated Radiotherapy) RADIATION Phase PHASE2 HPV-Related Squamous Cell Carcinoma ClinicalTrials.gov
    KP-1461 DRUG Phase PHASE1 HIV Infections ClinicalTrials.gov
    ISA101/ISA101b DRUG Phase PHASE1 Cervical Cancer ClinicalTrials.gov
    Hespecta BIOLOGICAL Phase PHASE1 Tumors or Premalignant Lesions ClinicalTrials.gov
    KPL-914 DRUG Phase PHASE2 Recurrent Pericarditis ClinicalTrials.gov
    Placebos DRUG Phase PHASE2 COVID-19 ClinicalTrials.gov
    Mavrilimumab DRUG Phase PHASE2 COVID-19 ClinicalTrials.gov
    Matching Placebo OTHER Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    KPL-404 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Rilonacept DRUG Phase PHASE3 Recurrent Pericarditis ClinicalTrials.gov
    prednisone DRUG Phase PHASE2 Giant Cell Arteritis ClinicalTrials.gov
    KPL-716 DRUG Phase PHASE2 Chronic Idiopathic Urticaria ClinicalTrials.gov
    Abiprubart DRUG Phase PHASE2 Sjögrens Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Kiniksa Pharmaceuticals
    • Ticker Symbol: KNSA

Search

News categories